Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 6/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.33 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20999352 | 0.99 | EPHX1 (0.38) | EPHX1ALOX15SMN1; SMN2PRMT1MEN1 | |
| SCHEMBL20999364 | 0.99 | EPHX1 (0.38) | EPHX1ALOX15SMN1; SMN2PRMT1MEN1 | |
| SCHEMBL6150091 | 0.84 | FOLH1 (0.38) | ALOX15SMN1; SMN2MEN1CYP1A2KMT2A | |
| SCHEMBL17553002 | 0.82 | DDAH1 (0.37) | ALOX15SMN1; SMN2MEN1CYP1A2KMT2A | |
| SCHEMBL27494369 | 0.82 | DDAH1 (0.37) | ALOX15SMN1; SMN2MEN1CYP1A2KMT2A | |
| SCHEMBL12210960 | 0.74 | NPY4R (0.39) | ALOX15SMN1; SMN2MEN1CYP1A2KMT2A | |
| SCHEMBL24135883 | 0.71 | C3AR1 (0.41) | SMN1; SMN2FOLH1 | |
| SCHEMBL27968072 | 0.71 | C3AR1 (0.34) | ALOX15SMN1; SMN2MEN1CYP1A2KMT2A | |
| SCHEMBL10929177 | 0.71 | NPY4R (0.38) | ALOX15SMN1; SMN2MEN1CYP1A2KMT2A | |
| SCHEMBL14203126 | 0.70 | TGFBR1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10836720-B2 | Inhibitors of integrin alpha 5 beta 1 and methods of use | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-11-17 | — | — | US | disclosed |
| US-20190144386-A1 | INHIBITORS OF INTEGRIN ALPHA 5 BETA 1 AND METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190144386-A1 | INHIBITORS OF INTEGRIN ALPHA 5 BETA 1 AND METHODS OF USE | ITGA5, ITGB5, ITGB1 | EPHX1 880/4885ALOX15 2312/4885SMN1; SMN2 3508/4885 |
| US-10836720-B2 | Inhibitors of integrin alpha 5 beta 1 and methods of use | ITGA5, ITGB5, ITGB1 | EPHX1 880/4885ALOX15 2312/4885SMN1; SMN2 3508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.